ArticleInternational journal of retina and vitreous2023

Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degeneration.

Joseph M Coney et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.